Why My Price Target for Valeant Pharmaceuticals Intl Inc. Is $0

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) should not be bought at any price.

| More on:
The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) reported unaudited results for the fourth quarter of 2015, and they were ugly to say the least. We’ll take a closer look at the numbers and also look at why the stock shouldn’t be bought at any price.

Very disappointing numbers

If there was any good news, it’s that Valeant generated US$2.8 billion during the fourth quarter. Otherwise, there is nothing positive to report.

Valeant’s Q4 earnings per share (EPS) came in at US$2.50, which was US$0.11 below consensus estimates. But the real bad news came when the company gave its updated guidance. For the year 2016, Valeant expects revenue between US$11 billion and US$11.2 billion, down from prior guidance of US$12.5-12.7 billion. EPS is expected to come in at US$9.50-10.50, again, down from prior guidance, which was US$13.25-13.75.

Even more worryingly, Valeant forecasted US$6.2-6.6 billion in adjusted EBITDA in the 12 months following March 31, but then lowered that estimate to US$6 billion during the earnings call. Management blamed the error on a “typo,” but it’s another sign that they don’t have a handle on their own business.

More trouble from here

Ever since Valeant’s relationship with Philidor was exposed, the company has found itself under increased scrutiny, and that seems to have affected the rest of its business. In the press release, Valeant noted that business slowed in a number of areas, even ones that weren’t a big part of Philidor. For example, Valeant’s gastrointestinal business experienced softer-than-expected sales in the fourth quarter.

This scrutiny will only grow more intense. Politicians are angry about Valeant’s high drug prices. Investigations from the SEC and other public bodies are ongoing. And we still haven’t gotten to the bottom of what was going on at Philidor.

A default could be looming

Valeant’s biggest problem now is its balance sheet. The company has over US$30 billion of debt on its books and has plans to pay down US$1.7 billion this year. But the efforts may not be enough.

If Valeant does not submit its annual report by Thursday, it will breach the covenants on its bonds, paving the way for a default. From there, the company will have a 60-day window to make the proper filings and avoid defaulting.

Here’s the problem though: after the latest numbers came in lower than expected, Valeant may have already breached one of its debt covenants. And that may be why the company has yet to release audited results. To be fair, that is just speculation at this point. But Valeant has also said it intends to enter into negotiations with its creditors regarding covenants.

This is why Valeant’s shares could easily reach $0, and I wouldn’t recommend buying the shares at any price. Put another way, this story is nowhere near over.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned.  Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Confused person shrugging
Dividend Stocks

Better Buy: Fortis Stock or Hydro One Stock?

Let's do a compare and contrast of these two top utilities stocks right now, shall we?

Read more »

A close up color image of a small green plant sprouting out of a pile of Canadian dollar coins "loonies."
Dividend Stocks

Boost Your Passive Income: 2 Canadian High-Yielders at a Bargain

Nutrien (TSX:NTR) stock and another play that appear like fantastic dividend bargains in mid-November.

Read more »

Super sized rock trucks take a load of platinum rich rock into the crusher.
Metals and Mining Stocks

Invest $7,000 in This Dividend Stock for $672 in Passive Income

High yield can be an essential requirement when you need to start even a modestly sized passive income with a…

Read more »

telehealth stocks
Tech Stocks

Well Health Stock: Buy, Sell, or Hold?

Another record-breaking quarter and strong demand sets the stage for continued momentum for Well Health stock.

Read more »

3 colorful arrows racing straight up on a black background.
Dividend Stocks

TSX Stocks Soaring Higher With No Signs of Slowing

Three TSX stocks continue to beat the market and could soar higher in an improving investment landscape.

Read more »

Hourglass and stock price chart
Dividend Stocks

Goeasy Stock: Is It Heading for a 52-Week High?

Goeasy stock has been edging higher, especially after another record-setting earnings report. So are 52-week highs in sight?

Read more »

Piggy bank with word TFSA for tax-free savings accounts.
Dividend Stocks

Here’s the Average TFSA Balance at Age 44 in Canada

You can invest your TFSA in funds like the BMO Canadian High Yield Dividend ETF (TSX:ZDV) to grow the balance.

Read more »

bulb idea thinking
Stocks for Beginners

2 Stocks That Could Help You Get Richer in 2025

It’s time to prepare for 2025 before you leave for the holidays. Here are two stocks that could make you richer…

Read more »